Capricor Therapeutics, Inc.
http://capricor.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Capricor Therapeutics, Inc.
BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
Eisai’s Alzheimer’s Pipeline Offers Combination Therapy Potential
Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Capricor Inc.
- Nile Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice